EMD Serono / Merck KGaA (Darmstadt, DE / Rockland, MA) sponsors 46 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (6 recruiting now), 18 completed protocols, and 19 all-time original FDA Drugs@FDA NDA and BLA approvals.